Oruka Therapeutics Q2 net loss widens to $41.2 million; cash totals $1.1 billion
Oruka Therapeutics reported second quarter 2026 results with a net loss of $41.2 million, up from $24.6 million a year earlier, as research and development and general and administrative expenses rose. The company had $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026, which it says will fund operations through an anticipated BLA filing for ORKA-001. The filing also updated pipeline timing, including Week 28 EVERLAST-A data expected at the end of the third quarter of 2026.
Key points
- Net loss was $41.2 million for Q2 2026 versus $24.6 million for Q2 2025.
- R&D expenses rose to $43.3 million from $24.1 million; G&A expenses rose to $6.9 million from $4.3 million.
- Other income, net was $8.9 million, driven mainly by interest on higher cash and marketable securities.
- EVERLAST-B Week 16 data is now expected in Q4 2026, and ORCA-SURGE Week 16 data is now expected in Q1 2027.
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.